CINCINNATI, OH--(Marketwire - January 10, 2012) -
Medpace, Inc. today announced the addition of Jason D. Hurt, MD as a Medical Director with responsibility for leading clinical drug development for Gynecologic Oncology. The addition of Dr. Hurt allows Medpace to provide deeper expertise in diseases specific to women, such as ovarian, cervical, and uterine cancer. This emerging area adds another layer of therapeutic expertise to the Medpace oncology team
"Dr. Hurt's contributions to the specialized area of gynecologic oncology represent a clear advantage for our Sponsors - providing a unique perspective to issues in drug development for women's cancers," said Jonathan Isaacsohn, MD, FACC, Executive Vice President, Medpace. "Medpace has built a growing consultancy in the broad spectrum of oncology. Dr. Hurt joins an existing Medpace oncology team, allowing Medpace to develop a leadership position at all levels of oncology drug development."
Dr. Hurt brings expertise to the Medpace medical management team from his research at Texas Tech University Health Sciences and The Ohio State University Medical Center. Dr. Hurt was most recently with the University of Pittsburgh Medical Center as an attending Obstetrician and Gynecologist.
Dr. Hurt received his Doctor of Medicine degree from Texas Tech University and has published a number of papers in regards to gynecologic malignancies.
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.
Visit the Medpace website at www.medpace.com